Advertisement
  • Evening Standard

    Why Harry Maguire has been left out of the England squad for Euro 2024

    Manchester United defender will miss tournament in Germany

  • Yahoo Finance Video

    How the Fed could challenge 'Goldilocks' FX market: Strategist

    The European Central Bank (ECB) has cut interest rates for the first time since 2019, from 4% to 3.75%. TD Bank Global Head of FX & EM Strategy Mark McCormick joins Catalysts to break down how the forex market is digesting the news and what the move could signal for the Federal Reserve's next interest rate decision. McCormick notes that the rate cuts were fully priced into the FX market, adding that the big piece is what the ECB will do next. While the markets want further insight, the ECB reiterated that its next moves will be data-dependent, which he explains "overtakes the ability for them to provide any credible forward guidance." Because of that, McCormick says that we're in a guessing game ahead of the ECB's next meeting in July. He adds, "The challenging part about the currency markets is it's always kind of multi-dimensional," as it constantly has to adapt to an evolving market. McCormick explains that with the US economy slowing while Europe recovers, "the market can't really make its mind up whether or not it wants to sell the dollar on the converging growth story, or whether or not it wants to buy the dollar on the diverging inflation story." He says that while many of the G10 central banks have cut rates, the Fed still has not made a move, which could "challenge this Goldilocks environment we're in where FX volatility is very low." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl

  • Benzinga

    Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile

    On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the data from Eli Lilly And Co’s (NYSE:LLY) Phase 3 Study AACI (TRAILBLAZER-ALZ 2) support a favorable benefit-risk assessment for the use of donanemab for Alzheimer’s disease. In March last year, Eli Lilly released the results of the TRAILBLAZER-ALZ 2 Phase 3 study of donanemab for Alzheimer’s disease. The document notes that the phase 2 study’s statistically sig